Allogeneic NK cells

DRUG3 trials

Sponsors

Seoul National University Hospital, Artiva Biotherapeutics, Inc., Paolo Caimi, MD

Conditions

B-cell Non Hodgkin LymphomaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaHigh-grade B-cell LymphomaIIMIdiopathic Inflammatory Myopathies (IIMs)Malignant Lymphomas

Phase 1

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

CompletedNCT01212341

Seoul National University HospitalMalignant Lymphomas, Solid Tumors

Start: 2010-09-30End: 2013-03-31Target: 18Updated: 2013-08-19

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

RecruitingNCT07225439

Paolo Caimi, MDB-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma +7

Start: 2026-09-01End: 2027-12-01Target: 15Updated: 2026-09-09

Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

RecruitingNCT06991114

Artiva Biotherapeutics, Inc.Idiopathic Inflammatory Myopathies (IIMs), IIM, Myositis +6

Start: 2025-07-09End: 2029-01-01Target: 90Updated: 2026-07-31